Biota Pharmaceuticals Inc  

(Public, NASDAQ:BOTA)   Watch this stock  
Find more results for BOTA
3.27
-0.07 (-2.10%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.15 - 3.44
52 week 2.35 - 7.07
Open 3.38
Vol / Avg. 0.00/80,993.00
Mkt cap 114.76M
P/E     -
Div/yield 1.11
EPS -0.28
Shares 35.10M
Beta 1.41
Inst. own 45%
Jun 2, 2014
Biota Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 8, 2014
Biota Pharmaceuticals Inc at Deutsche Bank Healthcare Conference
May 6, 2014
Q3 2014 Biota Pharmaceuticals Inc Earnings Conference Call
May 6, 2014
Q3 2014 Biota Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 10.85% -25.89%
Operating margin 10.85% -42.56%
EBITD margin - -62.50%
Return on average assets 12.63% -9.55%
Return on average equity 16.02% -13.71%
Employees 71 -
CDP Score - -

Address

Suite 100, 2500 Northwinds Parkway
ALPHARETTA, GA 30009
United States - Map
+1-678-2213343 (Phone)
+1-301-7703097 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�s researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan. The Company�s products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI).

Officers and directors

James Charles Fox Ph.D. Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Russell H. Plumb President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Joseph M. Patti Ph.D. Executive Vice President - Corporate Development & Strategy, Assistant Secretary
Age: 49
Bio & Compensation  - Reuters
Peter J. Azzarello CPA Chief Accounting Officer
Age: 42
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 56
Bio & Compensation  - Reuters
Richard James Hill Independent Director
Age: 67
Bio & Compensation  - Reuters
John Richard Independent Director
Age: 56
Bio & Compensation  - Reuters
Anne M. VanLent Independent Director
Age: 66
Bio & Compensation  - Reuters